Belgium Lung Cancer Therapeutics Market Report 2022 to 2030

Belgium Lung Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Belgium Lung Cancer Therapeutics Market will reach a value of $122 Mn from $66 Mn in 2022, growing at a CAGR of 8.1% during 2022-2030. The Lung Cancer Therapeutics Market in Belgium is dominated by a few domestic pharmaceutical companies such as Ion Beam Applications, Oncurious, and Oxurion. The Lung Cancer Therapeutics Market in Belgium is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Belgium lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies and the presence of highly efficient drugs.

ID: IN10BEPH041 CATEGORY: Pharmaceuticals GEOGRAPHY: Belgium AUTHOR: Dr. Vishwa Modhia

Buy Now

Belgium Lung Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Belgium Lung Cancer Therapeutics market will reach a value of $122 Mn from $66 Mn in 2022, growing at a CAGR of 8.1% during 2022-2030.

Belgium is a high-income, developed country in Western Europe that borders the North Sea. The Belgian Cancer Registry (BCR) is a population-based registry with national coverage beginning in 2004. In 2018, a total of 8815 new lung cancers were diagnosed: 5726 (65%) in men and 3089 (35%) in women. 9 This accounts for 13% of all new cancer diagnoses, making lung cancer the second and third most common disease in men and women, respectively.

The organisation of its "Bismarck type" health care is built on therapeutic independence for clinicians, patient choice, and fee-for-service payment. According to the latest WHO data published in 2020 Lung Cancers Deaths in Belgium reached 6,777 or 7.32% of total deaths. The age-adjusted Death Rate is 28.49 per 100,000 population ranks Belgium 16^th in the world. Belgium's government spends 11.1% of its GDP on healthcare.

Belgium Lung Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers

Belgium has the highest RT equipment density in the world, with 24 radiation treatment centres and 13 satellite facilities. Because of the 2008 National Cancer Plan (NCP) endorsement, cancer care is now required to be organised in multidisciplinary care programmes guided by structural and volume metrics. In 2002 and 2003, two royal decrees established multidisciplinary tumour boards (MDTBs) and oncological care programmes, respectively. In terms of commerce, Belgium is strategically placed between the United Kingdom, Germany, and France. Between 2012 and 2016, KCE-audit 5656 lung cancer resections were conducted, accounting for 17.7 per cent of all diagnosed lung malignancies. These aspects could boost Belgium's Lung Cancer Therapeutics market.

Market Restraints

There is currently no approved lung cancer screening programme in place for high-risk (ex)smokers. Because lung cancer screening is organised at the regional level, the request for a future lung cancer screening programme must be approved separately by the ministers of health of Flemish, Walloon, or Brussels. A major issue for oncologic thoracic surgery will be dealing with the predicted rise in surgical activity following the implementation of screening programmes, which will result in more early-stage lung cancer detections. Access to new systemic anticancer treatments is difficult in Belgium. These factors may deter new entrants into the Belgium Lung Cancer Therapeutics market.

Competitive Landscape

Key Players

Ion Beam Applications (IBA): Ion Beam Applications is a Belgian company that develops and produces proton therapy equipment and other advanced medical devices. The company offers proton therapy as a treatment option for lung cancer
Oncurious: Oncurious is a Belgian biotechnology company that focuses on the development of innovative therapies for the treatment of cancer
Oxurion: Oxurion is a Belgian biotechnology company that focuses on the development of innovative treatments for retinal diseases, including diabetic retinopathy

Recent Notable Updates

January 2023: DeuterOncology, based in Liege, Belgium, is a clinical-stage medication research firm seeking to advance in this sector. The Belgian business has now acquired $6.1 Mn in Series A funding from Belgian venture capitalists Newton Biocapital, Noshaq (who also backed Eclo and LiveDrop), and Investsud Tech. According to the firm news release, the cash will be used to begin Phase I clinical research for its main product, DO-2, an enhanced MET kinase inhibitor being developed to treat lung cancer.

Healthcare Policies and Reimbursement Scenarios

In Belgium, the regulatory authority responsible for the approval and regulation of therapeutic products, including lung cancer therapeutics, is the Federal Agency for Medicines and Health Products (FAMHP). The inclusion of a reimbursement fee has greatly aided in the successful implementation of these MDTBs and the development of integrated multidisciplinary cancer care programmes.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Lung Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Small Cell Lung Cancer
Non-small Cell Lung Cancer
Lung Carcinoid Tumor

By Therapy (Revenue, USD Billion):

Radiation Therapy
Targeted Therapy
Immunotherapy
Chemotherapy
Others

By Type of Molecule (Revenue, USD Billion):

Small Molecules
Biologics

By Drug Class (Revenue, USD Billion):

Alkylating Agents
Antimetabolites
Multikinase Inhibitors
Mitotic Inhibitors
EGFR Inhibitors
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.